3 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

3 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

3 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

3 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

3 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

3 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

3 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

3 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

3 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

3 - ONCOLYTICS BIOTECH INC (0001129928) (Issuer)

SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today provided additional context regarding its previously announced proposal to change the Company's jurisdiction of incorporation from Alberta, Canada, to the State of Nevada in the United States. The Company believes it is important to clearly communicate the strategic and operational reasons underlying this proposal as Oncolytics continues its transition into a U.S.-focused clinical-stage oncology company. Over the past several years, Oncolytics' operations, management team, shareholder base, and capital mar

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Biopharma M&A is entering a fever pitch, with precision oncology investments alone exploding to $138 billion as major players scramble to secure proven cancer therapies before their most profitable drugs lose protection[1]. This looming $170 billion "patent cliff" has triggered a massive capital rotation into de-risked platforms that can reach patients and the market within the next 18 to 24 months[2]. This urgent race for registration-ready assets is driving the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), OS Therapies Inc. (NY

Track 1 manufacturing patent application and additional planned filings to potentially extend patent coverage beyond 2044 Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today provided an update on the status of its intellectual property ("IP") portfolio and ongoing efforts to extend patent protection for pelareorep as part of the company's long-term value creation and development strategy. In early Q3 2025, Oncolytics filed a Track 1 prioritized examination patent application with the United States Patent and Trademark Office ("USPTO") focused on manufacturing-related innovations for pelareorep. If gr

Issued on behalf of GoldHaven Resources Corp. VANCOUVER, British Columbia, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Equity Insider Market Intelligence Brief – The era of abundance is over. The digital economy scales infinitely. The physical economy has hit a wall. We are running out of the inputs that make civilization function. Cheap uranium to power the grid. Strategic metals to build the defense stack. Clinical data to stop the cancer. Sovereign technology to secure the nation.The companies below don't sell growth. They own the bottleneck. If you cannot source the tungsten, you cannot build the missile. If you cannot extract the uranium, you cannot run the data center. If you cannot genera

Issued on behalf of Oncolytics Biotech Inc.  USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 7, 2026 /PRNewswire/ -- The global cancer drugs market is surging toward $594.3 billion by 2035 as high-tech immunotherapies begin to replace traditional chemotherapy[1]. With response rates now exceeding 90% in some previously untreatable blood cancers, these platforms are demonstrating a unique ability to reactivate a patient's own immune system to fight back[2]. This fundamental shift toward "reprogramming" the body's defenses drives the investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), BriaCell Therapeutics Corp. (NASDAQ:BCTX) (TSX:BCT), Greenwich LifeSciences, Inc. (NASDAQ:GLSI), C

New members bring deep experience in pancreatic, colorectal, and anal cancers to guide pelareorep's development as a platform immunotherapy across GI tumors Company continues to strengthen its clinical and strategic foundation to advance registration-enabling studies in high-value indications Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the expansion of its gastrointestinal ("GI") Tumor Scientific Advisory Board ("SAB") with the appointment of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris, three globally recognized experts in gastrointestinal oncology. The GI SAB was recent

Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, Dec. 31, 2025 /PRNewswire/ -- The precision oncology market surged to $139.4 billion in 2025 and is racing toward $317.5 billion by 2035[1], driven by a fundamental shift in cancer treatment philosophy. Biomarker-guided therapy selection now enables oncology pharmacists and clinicians to match treatments to tumor-specific characteristics rather than relying on blind, one-size-fits-all protocols[2]. This convergence of diagnostic precision and therapeutic targeting defines the investment thesis for Oncolytics Biotech Inc. (NASDAQ:ONCY), Exact Sciences Corp. (NASDAQ:EXAS), Veracyte, Inc. (NASDAQ:VCYT),

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Gastrointestinal cancers that once resisted checkpoint inhibitors are finally responding to novel combination strategies[1], with the FDA fast-tracking multiple targeted therapies designed to transform immunologically cold tumors into treatment-responsive hot targets[2]. This pivotal shift positions Oncolytics Biotech Inc. (NASDAQ:ONCY), AIM ImmunoTech (NYSE-American: AIM), ArriVent BioPharma, Inc. (NASDAQ:AVBP), Merus N.V. (NASDAQ:MRUS), and Halozyme Therapeutics, Inc. (NASDAQ:HALO) as potential leaders in the battle against stolid tumors, including gastrointestinal ca

VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways that could accelerate oncology breakthroughs[1]. This momentum is already materializing, with five major oncology approvals secured in November across multiple cancer indications, demonstrating regulators' willingness to green-light promising therapies when supported by compelling clinical data[2]. Against this backdrop of regulatory evolution, several clinical-stage biotechs are advancing toward definitive registration studies and commercial readiness, po

33% ORR achieved in second-line KRAS-mutant MSS colorectal cancer—triple historical response rates for Avastin + FOLFIRI of 6-11% Translational analysis shows pelareorep enhances KRAS-mutant–specific T-cell activity, providing mechanistic support for clinical responses Data strengthen pelareorep's potential to transform a multi–billion dollar underserved colorectal cancer market Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced clinical and translational findings supporting the development of pelareorep in second-line metastatic colorectal cancer ("mCRC"), specifically in patients with KRA

Lake Street initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $7.00

Maxim Group initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $3.00

H.C. Wainwright initiated coverage of Oncolytics Biotech with a rating of Buy and set a new price target of $15.00

425 - ONCOLYTICS BIOTECH INC (0001129928) (Subject)

6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

EFFECT - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

424B3 - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

F-4/A - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

6-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)

New members bring deep experience in pancreatic, colorectal, and anal cancers to guide pelareorep's development as a platform immunotherapy across GI tumors Company continues to strengthen its clinical and strategic foundation to advance registration-enabling studies in high-value indications Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced the expansion of its gastrointestinal ("GI") Tumor Scientific Advisory Board ("SAB") with the appointment of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris, three globally recognized experts in gastrointestinal oncology. The GI SAB was recent

Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care mo

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

SAN DIEGO and CALGARY, Alberta, June 30, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Andrew Aromando as Chief Business Officer. Mr. Aromando most recently served as Chief Operating Officer at Ambrx Biopharma, where his contributions were instrumental in the $2 billion acquisition of the San Diego-based biotech by Johnson & Johnson. In his role at Oncolytics, Mr. Aromando will be responsible for leading global business development. He will a

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

SAN DIEGO and CALGARY, AB, June 11, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Jared Kelly as Chief Executive Officer and a member of its Board of Directors. Mr. Kelly is a successful biotech executive who has proven expertise in transformative deals and corporate strategy. Most recently, he played a central role in orchestrating the sale of Ambrx Biopharma to Johnson & Johnson for $2 billion. Prior to Ambrx, he advised multiple leading-edge biotech companies on M&A and licensing transactions at highly respected law firms, including Lowenstein Sandler L

LONDON, Ontario and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- August 12, 2024. Sernova Corp. ("Sernova" or the "Company") (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, led by an ongoing phase 1/2a clinical trial in type 1 diabetes, is pleased to announce Mr. Jonathan Rigby as the Company's new Chief Executive Officer. James Parsons, on behalf of the Board of Directors of Sernova, stated, "The Board believes that Sernova is now positioned to achieve its strategic milestones under Jonathan's leadership. Jonathan brings a track record of success raising equi